[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-cancer-stage-iv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-cancer-stage-iv":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,69,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100635742","phase-2-lm-302-and-s-1-plus-intraperitoneal-paclitaxel-with-or-without-cadonilimab-for-claudin-182-positive-gastric-or-gastroesophageal-junction-adenocarcinoma-with-peritoneal-metastasis-a-prospective-exploratory-study-100635742",false,"NCT07556640","LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study","LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis: a Prospective, Exploratory Study","Inclusion Criteria:\n\n* Histologically confirmed gastric or gastroesophageal junction adenocarcinoma with her 2 (-), and without the history of resection of primary or metastatic lesion;\n* Age ≥ 18 years at registration;\n* Peritoneal metastases from gastric cancer requiring definitive diagnosisby laparoscopy, and without gastric outflow tract obstruction andintestinal obstruction;\n* Claudin 18.2 positive (≥ 25%, moderate to strong staining);\n* Eastern Cooperative Oncology Group (ECOG) score ≤ 1;\n* Expected life expectancy \\> 3 months;\n* Adequate bone marrow, liver, and renal functions.\n\nExclusion Criteria:\n\n* Presence of distant metastases other than peritoneal metastasis at the time of enrollment;\n* Pregnant or breastfeeding women;\n* Prior treatment with Claudin 18.2 targeted therapy;\n* History of other malignancies within the past 5 years, except for cured skin cancer or cervical carcinoma in situ;\n* History of uncontrolled epilepsy, central nervous system disease, or mental disorder that, in the investigator's judgment, may interfere with signing informed consent or compliance with oral medication.\n* Clinically significant active heart disease, such as symptomatic coronary artery disease, New York Heart Association (NYHA) class II or higher congestive heart failure, severe arrhythmia requiring medication, or myocardial infarction within the past 12 months;\n* Upper gastrointestinal obstruction, abnormal physiological function, or malabsorption syndrome that may affect S 1 absorption;\n* Known peripheral neuropathy ≥ NCI CTC AE grade 1. However, patients with loss of deep tendon reflexes (DTR) alone may be included;\n* Organ transplantation requiring immunosuppressive therapy;\n* Severe uncontrolled recurrent infection or other severe uncontrolled concomitant diseases;\n* Moderate or severe renal impairment (creatinine clearance ≤ 50 ml\u002Fmin) or serum creatinine above the upper limit of normal;\n* Known dihydropyrimidine dehydrogenase (DPD) deficiency;\n* Active hepatitis (for hepatitis B: HBsAg positive and HBV DNA ≥ 500 IU\u002Fml; for hepatitis C: HCV antibody positive and HCV viral load \\> upper limit of normal);\n* Psychiatric disorder that makes the patient unable to comply with treatment;\n* Allergy to paclitaxel or any component of the study drugs;\n* History or evidence of any disease, condition, treatment, or laboratory abnormality that could interfere with the study results or the patient's full participation, or any other condition that, in the investigator's opinion, makes the patient unsuitable for enrollment.","ALL","18 Years",{"count":19,"type":20},74,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","In this study, the investigators will use LM-302 and S-1 plus intraperitoneal paclitaxel with or without Cadonilimab to treat Claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis.",[26,27,28],"Gastric Cancer Stage IV","Peritoneal Metastases From Gastric Cancer","Gastric or Esophagogastric Junction Adenocarcinoma",[30,31,32,33,34,28],"Gastric cancer","Peritoneal metastasis","Claudin 18.2","Cadonilimab","Paclitaxel","RECRUITING","2026-04-24",{"date":38,"type":39},"2026-04-29","ACTUAL",{"date":41,"type":39},"2026-04-17",{"date":43,"type":20},"2029-04-30",{"name":45,"class":46},"Ruijin Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":47},"100556015","phase-2-systemic-application-of-cadonilimab-lm-302-and-s-1-combined-with-intraperitoneal-infusion-of-paclitaxel-for-the-treatment-of-claudin-182-positive-gastric-cancer-with-peritoneal-metastasis-100556015","NCT06519591","Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis","Inclusion Criteria:\n\n1. Histologically confirmed gastric adenocarcinoma with her 2 (-), and without the history of resection of primary or metastatic lesion;\n2. Peritoneal metastases from gastric cancer requiring definitive diagnosis by laparoscopy, and without gastric outflow tract obstruction and intestinal obstruction; Written (signed) informed consent;\n3. Claudin 18.2 positive (≥ 25%, and the proportion of positive cells greater than 50% of the cases accounted for not less than 70%);\n4. Age ≥ 18 years at registration;\n5. Eastern Cooperative Oncology Group (ECOG) score ≤ 1;\n6. Expected life expectancy \\> 3 months;\n7. Adequate bone marrow, liver, and renal functions.\n\nExclusion Criteria:\n\n1. Confirmed of evidence of distant metastasis other than peritoneal metastasis (e.g.liver metastasis, lung metastasis, para-aortic lymph node metastasis, etc.);\n2. During pregnancy, within 28 days of post parturition, or during lactation;\n3. Previously received immunotherapy such as PD-1\u002FPD-L1 and CTLA-4 or targeted therapy such as Claudin 18.2.\n4. Synchronous or metachronous (within 5 years) malignancies.\n5. Severe mental disease, uncontrolled epilepsy, or central nervous system disease;\n6. Clinically severe (i.e. active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure or arrhythmia requiring drug intervention, or a history of myocardial infarction in the last 12 months;\n7. Upper gastrointestinal obstruction or abnormal physiological function or malabsorption syndrome may affect S-1 absorbers;\n8. Known peripheral neuropathy (\\> NCI-CTC AE 1). However, patients with only disappearance of deep tendon reflex (DTR) need not be excluded;\n9. Patients on steroid or immunosuppressant treatment after organ transplant;\n10. Patients with severe uncontrolled recurrent infections or other severe uncontrolled concomitant disease;\n11. Moderate or severe renal damage \\[creatinine clearance ≤ 50 ml\u002Fmin\\], or serum creatinine \\> upper limit of normal (ULN), 115 μmol\u002FL;\n12. Known dihydropyrimidine dehydrogenase (DPD) deficiency;\n13. Anaphylaxis to paclitaxel or any research drug ingredient.\n14. Active autoimmune disease or history of refractory autoimmune disease;\n15. Subjects with hypothyroidism requiring only hormone replacement therapy and skin diseases without systemic treatment (such as vitiligo, psoriasis or alopecia) can be selected;\n16. HIV antibody positive, active hepatitis B or C (hepatitis B: HBsAg positive and HBV DNA ≥10 copies\u002Fml; hepatitis C: HCV antibody and HCV-RNA positive, requiring antiviral treatment at the same time);\n17. Steroid or other systemic immunosuppressive therapy was used 14 days before admission, excluding local or physiological doses of systemic glucocorticoids (eg. no more than 10mg\u002Fday of prednisone or other glucocorticoids of equivalent dose) by nasal spray, inhalation or other routes, or hormones used to prevent allergy of contrast agents;\n18. Uncontrolled arrhythmia and myocardial infarction within 12 months before admission or active tuberculosis.",{"count":55,"type":20},40,[23],"In this phase 2 study, we combined Cadonilimab, LM-302, and S-1 combined with intraperitoneal infusion of paclitaxel as regimen to treat gastric cancer patients with peritoneal metastasis.",[26,59],"Peritoneal Metastases",[30,31,33,32,34],"2026-02-13",{"date":63,"type":39},"2026-02-18",{"date":65,"type":39},"2025-02-25",{"date":67,"type":20},"2026-12",{"name":45,"class":46},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":47},"100407959","phase-1-pembrolizumab-olaparib-recurrentadvanced-gastric-and-gastro-esophageal-junctiongej-cancer-100407959","NCT04592211","Pembrolizumab, Olaparib, Recurrent\u002FAdvanced Gastric and Gastro-esophageal Junction(GEJ) Cancer","An Open Label, Single-Arm, Multi-center Phase Ib\u002FII Study to Evaluate the Efficacy of Paclitaxel in Combination With Pembrolizumab and Olaparib as a Second Line Treatment in Immune Checkpoint Inhibitor-experienced Recurrent\u002FAdvanced Gastric and Gastro-esophageal Junction(GEJ) Cancer.","Inclusion Criteria:\n\n1. Provided written informed consent for treatment.\n2. Age ≥ 19 years old\n3. measurable or evaluable disease based on RECIST 1.1. Lesions\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 on time of patient's allocation.\n5. Adequate organ function as defined by the following criteria:\n6. A life expectancy of at least 3 months\n7. Is able to swallow and retain orally administered medications\n8. Failed first-line trastuzumab treatment for HER2 positive patients\n9. Highly effective contraception for both male and female subjects if the risk of conception exists.\n10. Left ventricular ejection fraction (LVEF) ≥50%\n\nExclusion Criteria:\n\n1. A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation\n2. Has received prior systemic anti-cancer therapy including investigational agents within 2 weeks prior to allocation.\n3. Has received prior radiotherapy within 2 weeks of start of study treatment.\n4. Has received a live vaccine within 30 days prior to the first dose of study drug.\n5. Is currently participating in or has participated in a study of an investigational agent including trastuzumab or has used an investigational device within 4 weeks prior to the first dose of study treatment.\n6. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.\n7. Has a known additional malignancy that is progressing or has required active treatment within the past 5 years.\n8. Has known active CNS metastases and\u002For carcinomatous meningitis.\n9. Has severe hypersensitivity (≥Grade 3) to pembrolizumab and\u002For any of its excipients, PARP inhibitor and paclitaxel.\n10. Has active autoimmune disease that has required systemic treatment in the past 2 years\n11. Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.\n12. Has an active infection requiring systemic therapy.\n13. Has a known history of Human Immunodeficiency Virus (HIV).\n14. Has an active of Hepatitis B (defined as Hepatitis B surface antigen \\[HBsAg\\] reactive and HBV titer \\>2000 IU\u002Fml) or known active Hepatitis C virus (defined as HCV RNA is detected) infection.\n15. Has an active TB (Bacillus Tuberculosis) with treatment.\n16. Participant has received previous allogenic bone-marrow, tissue\u002Fsolid organ transplant or double umbilical cord transplantation (dUCBT).","19 Years",{"count":78,"type":20},71,[80,23],"PHASE1","Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). Olaparib is a potent PARP inhibitor (PARP1, 2, and 3) that is being developed as a monotherapy as well as for combination with chemotherapy, ionizing radiation, and other anti-cancer agents including novel agents and immunotherapy. Paclitaxel is widely used in breast, lung and gastric cancer with every 3-week or weekly cycle. Various targeted anticancer agents have been investigated with paclitaxel and combination with ramucirumab, a monoclonal anti-VEGFR2 antibody, was approved as a 2nd line treatment.",[26],"2025-07-09",{"date":85,"type":39},"2025-07-11",{"date":87,"type":39},"2021-10-01",{"date":89,"type":20},"2026-05-31",{"name":91,"class":46},"Yonsei University",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":47},"100463818","phase-1-phase-iii-study-of-the-combination-of-irinotecan-and-pof-pofi-and-tislelizumab-100463818","NCT05319639","Phase I\u002FII Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab","Phase I\u002FII Study of the Combination of Irinotecan and POF (Paclitaxel Plus Oxaliplatin Plus 5-fluorouracil Plus Leucovorin) and Tislelizumab","Inclusion Criteria:\n\n1. Patients with advanced unresectable, histologically confirmed adenocarcinoma of the gastric or gastroesophageal junction.\n2. With or without measurable lesions.\n3. Patients must have a performance status of 0-1 on the Eastern Cooperative Oncology Group (ECOG) scale.\n4. Without serious system dysfunction and could tolerate chemotherapy. With normal marrow, liver and renal function: a hemoglobin (HGB) of ≥100g\u002FL (without blood transfusion during 14 days); a leucopenia count of ≥4.0×109\u002FL; a platelet count of ≥100×109\u002FL; a total bilirubin (TBil) of ≤1.5 upper normal limitation (UNL); a creatinine (Cr) of ≤ 1.5 UNL; a creatinine clearance rate ≥ 50ml\u002Fmin (Cockcroft-Gault); a alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of ≤2.5 UNL or ≤5 UNL in case of liver metastasis.\n5. Life expectancy ≥3 months.\n6. With normal electrocardiogram results and no history of congestive heart failure.\n7. With normal coagulation function: activated partial thromboplastin time (APTT), prothrombin time (PT) and INR, each ≤ 1.5 x ULN.\n8. Female subjects of child-bearing potential must agree to use contraceptive measures starting 1 week before the administration of the first dose of Tislelizumab until 8 weeks after discontinuing study drug. Male subjects must agree to use contraceptive measures during the study and 8 weeks after last dose of study drug\n9. With written informed consent signed voluntarily by patients themselves or their supervisors witted by doctors.\n10. With good compliance and agree to accept follow-up of disease progression and adverse events.\n\nExclusion Criteria:\n\n1. Patients with a history of another neoplastic disease within the past three years, excluding basal cell carcinoma of the skin, cervical carcinoma in situ, or nonmetastatic prostate cancer.\n2. Patients with brain or central nervous system metastases, including leptomeningeal disease.\n3. Pregnant (positive pregnancy test) or breast feeding.\n4. Serious, non-healing wound, ulcer, or bone fracture.\n5. Significant cardiac disease as defined as: unstable angina, New York Heart Association (NYHA) grade II or greater, congestive heart failure, history of myocardial infarction within 6 months Evidence of bleeding diathesis or coagulopathy.\n6. History of a stroke or CVA within 6 months.\n7. Clinically significant peripheral vascular disease.\n8. Inability to comply with study and\u002For follow-up procedures.\n9. Patients with any other medical condition or reason, in that investigator's opinion, makes the patient unstable to participate in a clinical trial.","75 Years",{"count":101,"type":20},51,[80,23],"The purpose of the phase I\u002FII study is to establish the safety of Combination of Irinotecan and paclitaxel with 5-FU, leucovorin, oxaliplatin and Tislelizumab.",[26],"2025-02-26",{"date":107,"type":39},"2025-02-27",{"date":109,"type":39},"2023-02-16",{"date":111,"type":20},"2025-12-31",{"name":113,"class":114},"Fujian Cancer Hospital","OTHER_GOV"]